Novo Nordisk faces rising pressure as LLY launches Foundayo, a rival obesity pill, challenging Wegovy despite data suggesting ...

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to invest in for long-term growth. Eli Lilly and Company (NYSE:LLY) launched the easy-to-use injector pen of its weight-loss and diabetes ...

Eli Lilly (LLY) is considering testing its blockbuster weight-loss drugs in individuals who are not yet overweight but are at risk of weight gain, according to an exclusive Financial Times report.

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their GLP-1 products. Novo Nordisk markets its semaglutide drugs as Ozempic ...